UNSPSC 51121916: Carsatrin

This classification denotes a cardiotonic agent with the molecular formula C25H26F2N6OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 2E3S34L69I chemically known as 1-piperazineethanol, 4-(bis(4-fluorophenyl)methyl)-.alpha.-((9h-purin-6-ylthio)methyl)-, (+/-)- but generally known as carsatrin, which bears US NIH Compound Identifier 72049. European Medicines Agency schedules Carsatrin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06147MIG.

UNSPSC 51121916 Carsatrin (Commodity) encompasses emergency and acute-care medications supplied to fire rescue services, health agencies, and pharmacy benefit programs operated by state and local governments. State and local agencies procure specific advanced life support medications—such as epinephrine, labetalol, adenosine, and diltiazem—through sealed competitive bids, cooperative purchasing agreements, and requests for information that establish either direct supply relationships or access to medications through authorized wholesalers. Issuing bodies span city fire departments (Tampa Fire Rescue through the City of Tampa's Purchasing Department), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). These jurisdictions procure medications to support emergency medical services, state employee pharmacy benefit programs, and participating member agencies across multiple states.

Recent activity appears concentrated in Texas and Minnesota, with a significant city-level procurement in Florida. The City of Tampa issued an IFB (Solicitation 26P00188) in April 2026 for four specific Advanced Life Support Medications line items totaling an estimated $40,000, with award to the lowest responsive, responsible bidder and a SLBE sheltered-market designation offering a 5 percent bid discount (not to exceed $10,000); delivery must occur within ten calendar days of order receipt, with medications maintaining nine months or more until expiration and one-year warranty coverage. The Minnesota Department of Administration, through MMCAP, posted an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) to state and local facilities in Minnesota and Oregon, with evaluation weighted 75 percent on price competitiveness, and a two-year contract term effective July 1, 2026. The Texas HHS Commission issued an RFI (HHS0017013) in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling intent to establish direct contracting relationships between the state pharmacy benefit program and manufacturers outside traditional PBM and GPO channels.